Prompt restoration of coronary artery patency in acute myocardial infarction is associated with substantial improvements in morbidity and mortality. The pivotal role of thrombolysis and aspirin in achieving these goals is well established. However, despite the success of thrombolytic therapy in large trials, clinical assessment in individual patients often suggests that reperfusion has not occurred after initial therapy. This review considers the validity of such bedside predictions and discusses whether such patients should be managed differently.
With the success of thrombolytic therapy in reducing mortality from myocardial infarction, has come an appreciation of its limitations. Increasing evidence links the initial objective of early, complete and sustained recanalisation of the infarct-related artery with improved outcome (figure); yet 90 minutes after the initiation of thrombolytic therapy only just over half of treated patients will have complete reperfusion.' Although many infarct arteries occluded at this time will go on to re-open spontaneously within a time window during 
Rethrombolysis
The majority of myocardial infarctions are treated in centres without access to interventional facilities. Possible therapeutic approaches to increasing arterial patency in these centres include repeat thrombolysis with either the same or an alternative agent. Initial therapy with more than one thrombolytic agent in an attempt to improve reperfusion rate and maintain arterial patency has not been shown to improve outcome.'7 Conversely, repeat thrombolysis for early recurrent ischaemia following successful reperfusion is of benefit.'8 Is there evidence to support repeat thrombolysis where early reperfusion is not obtained?
Perhaps surprisingly, to date there are limited data with which to address this question. Rescue thrombolysis with intracoronary recombinant tissue plasminogen activator (rtPA) does appear to achieve high patency rates in patients with coronary thrombi initially resistant to streptokinase,"9 but this must be set against the potential for spontaneous late reperfusion. In the only randomised trial of rescue thrombolysis with rtPA for patients with failed reperfusion as assessed by the surface EGG, Mounsey 
